GeneDx Holdings Corp. (WGS) Financial Statements
GeneDx Holdings Corp. (WGS) reported trailing twelve-month revenue of $454.4M (up 25.4% year on year) and net income of -$106.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$75.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
WGSGeneDx Holdings Corp.Follow WGS — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 26 Oct, in 2 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 212.2 | 234.7 | 202.6 | 305.5 | 427.5 | 454.4 | |
| Gross profit | -16.6 | -26.8 | 90.0 | 194.4 | 298.2 | 315.2 | |
| Research & development | 105.2 | 86.2 | 58.3 | 45.7 | 72.0 | 83.8 | |
| Operating income | -446.1 | -667.7 | -180.6 | -23.2 | -13.1 | -92.4 | |
| Pre-tax income | -245.4 | -598.0 | -176.7 | -52.6 | -21.1 | -106.3 | |
| Income tax | 0.0 | -49.1 | -0.9 | -0.3 | -0.1 | 0.1 | |
| Net income | -245.4 | -549.0 | -175.8 | -52.3 | -21.0 | -106.4 | |
| Diluted EPS ($) | -2.27 | -53.63 | -7.23 | -1.94 | -0.73 | -3.64 | |
| Diluted shares (mn) | 108.1 | 10.2 | 24.3 | 26.9 | 28.6 | — |
USD millions · SEC XBRL
GeneDx Holdings Corp. — questions
- What is GeneDx Holdings Corp.'s revenue?
- $454.4M over the twelve months to 2026-06-30, up 25.4% year on year, from its 10-Q and 10-K filings.
- What is GeneDx Holdings Corp.'s net income?
- -$106.4M over the twelve months to 2026-06-30.
- What is GeneDx Holdings Corp.'s free cash flow?
- -$75.8M over the twelve months to 2026-06-30.
- What are GeneDx Holdings Corp.'s diluted earnings per share?
- $-3.64 over the twelve months to 2026-06-30.
Every figure on this page comes from GeneDx Holdings Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.